Table 1.

Inclusion Criteria of patients for PSMA-RGS.

Year	Country	Inclusion Criteria
Primary PCa
201513	Germany	Primary PCa and suspicion of recurrent LNMs on preoperative PSMA PET/CT
2018[38], 2021[49]	Germany	Suspicion of LNMs on preoperative PSMA PET/CT
202250	Italy	Intermediate- or high-risk cN0cM0 PCa at conventional imaging with a risk of LNI of >5% (Briganti nomogram risk)
202251	Australia	Primary high-risk PCa (≥cT3a, international society of urological pathology (ISUP) Grade Group ≥3 or PSA of ≥ 15 ng/mL) with potential LNMs (Briganti nomogram risk >10% or on preoperative imaging)
Recurrent PCa
201637	Germany	Rising PSA level to ≥0.2 ng/mL after primary curative therapy;68Ga-PSMA-11 PET-positive soft tissue lesions
201845	Germany	Recurrent PCa on preoperative PSMA PET/CT
202242	Netherlands	Up to three pelvic PCa recurrences (nodal or local) on preoperative PSMA PET/CT
202254	Germany	Recurrent PCa after initial RP with positive LNMs on preoperative PSMA PET/CT
202342	Germany	Patients with positive lesion detected on PSMA PET imaging in the pelvis or retroperitoneum suspicious for lymph node metastases (LNMs) or local recurrence.
202369	Germany	Conforming initial treatment with either radical prostatectomy (RPE) or curatively intended external beam radiation, prostate-specific antigen (PSA) ≥0.5 ng/mL, positive 68Ga-PSMA I&T PET/CT scan with no more than 2 intense PSMA-positive lymph nodes (maximum uptake at least 6 kBq/mL), and no signs of local recurrence or distant metastases, as well as informed consent to participate in this study.